Journal of Clinical Oncology
Articles in this Issue
Association of social environment with clinically meaningful declines in health-related quality of life domain bother and function in individuals after prostate cancer treatment.
e17025 Background: Clinically meaningful (CM) changes in function and bother have a significant impact on health-related q...
State-level trends in colorectal cancer incidence and stage before and during the COVID-19 pandemic.
e15709 Background: Colorectal cancer (CRC) incidence differs across U.S. states, in part reflecting socioeconomic and rura...
Phase 1, first-in-human, open-label study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of TGW101 in patients with advanced solid tumors.
TPS3163 Background: Tumor-associated glycoprotein 72 (TAG-72) is a non-internalizing glycoepitope that is aberrantly expre...
Longitudinal assessment of treatment information needs in an advanced prostate cancer online support group, 2016-2025.
e17056 Background: We see a growing trend in patients and caregivers using peer-led online communities for treatment advic...
MPOWER: A pilot trial among men with prostate cancer—Optimizing wellness by enhanced relief from hot flashes with acupuncture.
TPS12170 Background: Prostate cancer is the most commonly diagnosed cancer among men, and advanced disease often requires...
Phase I study of intraperitoneal fast-manufactured IL-9-secreting CEACAM5-targeted CAR-T cells in advanced colorectal cancer with peritoneal metastases.
3514 Background: Colorectal cancer peritoneal metastasis (CRPM) remains an unmet clinical need with poor prognosis and lim...
Radiotherapy use among locally advanced cervical cancer patients (LACC) in the United States community oncology setting.
5523 Background: Brachytherapy with concurrent chemoradiation +/- pembrolizumab is the current standard of care for LACC....
Targeting MAN1A1 to address immune checkpoint inhibitors resistance: A novel mechanism of vascular-endothelial reprogramming in NSCLC.
2566 Background: Despite the efficacy of immune checkpoint inhibitors (ICIs) in NSCLC, resistance remains a major hurdle....
Frontline intensified vs standard immunochemotherapy in high-risk diffuse large B-cell lymphoma: A systematic review and meta-analysis.
7065 Background: While the phase III CALGB 50303 trial comparing frontline REPOCH vs standard RCHOP for diffuse large B-ce...
Diagnostic performance, safety, and biodistribution of [ <sup>68</sup> Ga]Ga-OncoCAIX for PET/CT imaging: A first-in-human phase I clinical trial in clear cell renal cell carcinoma.
3075 Background: Conventional imaging techniques are routinely used in clear cell renal cell carcinoma (ccRCC). However, t...
Inferring optimal detection of homozygous loss (homozygous deletion) in head and neck cancer: Associations with HPV status, primary disease site, and clinical outcomes.
6071 Background: Validated detection of homozygous loss is becoming increasingly important in clinical practice. Examples...
Understanding psychological distress during chemotherapy: Assessment of anxiety and depression in Middle Eastern cancer patients.
e24117 Background: Anxiety and depression are common but often under-recognized in patients receiving chemotherapy and may...
EIK1003, a PARP1-selective inhibitor, in combination with paclitaxel (PTX): Initial combination and updated monotherapy results from a phase 1/2 study EIK1003-001 in advanced solid tumors.
3102 Background: Non-selective PARP inhibitors (PARPi) demonstrate efficacy in HRR-mutant tumors but cause myelosuppressio...
Cadonilimab in combination with chemotherapy versus chemotherapy alone in patients with immunotherapy-refractory recurrent or metastatic nasopharyngeal carcinoma: A multicenter, randomized, phase III trial the CONQUEST trial).
6033 Background: Chemotherapy combined with immune checkpoint inhibitors (ICIs) is the standard first-line treatment for r...
Large language model protein set generation for interpretable serum proteomics in localized prostate cancer.
5110 Background: High-plex serum proteomics can track prostate cancer biology and treatment response beyond PSA, but inter...
Reproductive outcomes after chemotherapy in young women with non-Hodgkin lymphoma: A systematic review and meta-analysis.
e19098 Background: With improving survival in young women with non-Hodgkin lymphoma (NHL), fertility outcomes have become...
Clinical burden and downstream consequences of severe fluoropyrimidine-associated toxicity in a single-center study.
e24176 Background: Fluoropyrimidines are widely used in the treatment of gastrointestinal and other solid tumors but are a...
Improving germline genetic testing rates among newly diagnosed breast cancer patients.
e22645 Background: Germline genetic testing is important for newly diagnosed breast cancer (BC) patients (pts) as results...
A phase II trial of tagraxofusp, hyper-CVAD, and venetoclax for patients with newly diagnosed or relapsed/refractory BPDCN.
6502 Background: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic malignancy with (w...
Randomized multicenter phase II trial of radioimmunotherapy versus chemoimmunotherapy followed by surgery for c-stage IB-III NSCLC (RICHIS trial).
TPS8132 Background: Chemotherapy combined with PD-1 or PD-L1 blockade (chemo-immunotherapy, ChemoIO), administered in the...
Vididencel, an active immunotherapy in high-grade serous ovarian carcinoma patients: Analysis of tumor-directed immune responses post-primary treatment.
5597 Background: Ovarian cancer (OC) remains the most common cause of mortality in gynecologic cancers, with advanced-stag...
An external validation of the IMmotion151 molecular subtypes in patients with advanced renal cell carcinoma using the ORIEN database.
4529 Background: There is a major unmet need for novel biomarkers in advanced renal cell carcinoma (RCC). A promising cand...
Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone (CHEPA) in newly diagnosed CD30-positive peripheral T-cell lymphomas with integrated ctDNA analysis: Results of the phase 2 CHEPA trial.
7081 Background: Peripheral T-cell lymphomas (PTCLs) are aggressive malignancies associated with poor outcomes. While addi...
Efficacy of neoadjuvant TCHP with primary empegfilgrastim (E) prophylaxis in HER2-positive early breast cancer (HER2+ eBC): Final results of the DEFENDOR SPECIAL study.
e12651 Background: Neoadjuvant therapy (NAT) is the current standard of care for treating HER2-positive breast cancer. Ach...
Prevalence of myelodysplastic syndrome and acute myeloid leukemia among hospitalizations with sickle cell disease: A National Inpatient Sample analysis.
e18545 Background: Sickle cell disease (SCD) is characterized by chronic bone marrow stress, inflammation, and high cellul...